SMAIO SA

SMAIO's capital structure shows a market cap of EUR 49.06 million with a price-to-book ratio of 8.16, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by a current ratio of 2.83, suggesting adequate short-term liquidity, but its free cash flow of EUR -2.52 million and negative operating income of EUR -2.61 million highlight operational cash flow challenges. Profitability metrics reveal a return on equity of -37.09% and a return on assets of -15.8%, both significantly below industry norms for medical device firms. Gross profit of EUR 8.01 million on revenue of EUR 9.16 million indicates a 87.5% gross margin, which is strong but insufficient to offset operating losses. The company's debt-to-equity ratio of 0.79 suggests moderate leverage, but its net cash position is negative after subtracting total debt, signaling potential refinancing risks. Geographically, SMAIO's revenue concentration is not disclosed in the input data, but its operations are centered in France. The company's product portfolio includes the Kheiron Spinal Fixation System and software solutions like Keops and Balance Analyzer 3D. These offerings are targeted at spine surgeons and focus on surgical planning and patient data management, which are key differentiators in the medical device industry. Growth trajectory is mixed. The company reported a revenue of EUR 9.16 million in the latest period, but no prior-year data is provided to assess year-over-year growth. Analysts have set a mean price target of EUR 8.30, slightly above the current market price of EUR 7.98, indicating a modest upside potential. However, the absence of positive operating income and free cash flow suggests that growth is not yet translating into profitability. Risk factors include liquidity constraints and the potential for dilution, though the latter is currently assessed as low. The company's negative operating cash flow and free cash flow indicate a reliance on external financing, which could lead to increased debt or equity issuance. The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after debt. Recent events include the publication of the latest financial snapshot and analyst estimates. The company has not disclosed any recent filings or transcripts, but the analyst price targets suggest a cautious outlook. The mean recommendation of 1.50 (on a scale of 1 to 5) indicates a slight bias toward buy, but the lack of strong buy or buy ratings beyond one each suggests limited conviction among analysts.